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NCPH is a heterogeneous group of liver disorders of vascular ori-
gin, leading to PHT with near normal HVPG. NCPF/IPH is a disor-
der of young adults or middle aged women, whereas EHPVO is a
disorder of childhood. Early age acute or recurrent infections in
an individual with thrombotic predisposition constitute the likely
pathogenesis. Both disorders present with clinically signiﬁcant
PHT with preserved liver functions. Diagnosis is easy and can
often be made clinically with support from imaging modalities.
Management centers on control and prophylaxis of variceal
bleeding. In EHPVO, there are additional concerns of growth fal-
tering, portal biliopathy, MHE and parenchymal dysfunction. Sur-
gical shunts are indicated in patients with failure of endotherapy,
bleeding from sites not amenable to endotherapy, symptomatic
hypersplenism or symptomatic biliopathy. Persistent growth fail-
ure, symptomatic and recurrent hepatic encephalopathy,
impaired quality of life or massive splenomegaly that interferes
with daily activities are other surgical indications. Rex-shunt or
MLPVB is the recommended shunt for EHPVO, but needs proper
pre-operative radiological assessment and surgical expertise.
Both disorders have otherwise a fairly good prognosis, but need
regular and careful surveillance. Hepatic schistosomiasis, CHF
and NRH have similar presentation and comparable prognosis.
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Portal hypertension (PHT) is a clinical syndrome deﬁned by a
portal venous pressure gradient between the portal vein (PV)
and inferior vena cava exceeding 5 mmHg [1]. Cirrhotic PHT
is associated with an elevated hepatic venous pressure gradient
(HVPG) predominantly due to raised sinusoidal resistance,
while in the non-cirrhotic PHT (NCPH), HVPG is normal or only
mildly elevated and is signiﬁcantly lower than PV pressure. The
diseases leading to NCPH are primarily vascular in nature and
classiﬁed anatomically on the basis of site of resistance to
blood ﬂow, as prehepatic, hepatic, and post-hepatic – hepatic
causes are further subdivided into pre-sinusoidal, sinusoidal
and post-sinusoidal (Table 1) [2,3]. Most of the times, PHT is
a late manifestation of the primary disease. However, non-cir-
rhotic portal ﬁbrosis (NCPF) and extra-hepatic PV obstruction
(EHPVO) are two disorders, which present only with features
of PHT without any evidence of signiﬁcant parenchymal dys-
function [2–5]. In this review, an updated account of these
two clinical entities along with some of the other causes will
be presented.Non-cirrhotic portal ﬁbrosis (NCPF)
Non-cirrhotic Portal Fibrosis (NCPF) variously called as Idiopathic
PHT (IPH), hepatoportal sclerosis and obliterative venopathy, is a
disorder of unknown etiology, clinically characterized by features
of PHT; moderate to massive splenomegaly, with or without
hypersplenism, preserved liver functions, and patent hepatic
and portal veins [2,3] (Table 2).
The disease has been reported from all parts of the world,
more so from the developing countries [6–16]. According to
the consensus statement of the Asia Paciﬁc Association for
the Study of the Liver (APASL) on NCPF, the disease accounts
for approximately 10–30% of all cases of variceal bleed in sev-
eral parts of the world including India [17]. It is more common
in young males in third to fourth decades belonging to low
socioeconomic groups [2,9–13]. A disease mimicking NCPF,
known as IPH in Japan and idiopathic non-cirrhotic PHT in
the West, has female preponderance and presents around the
ﬁfth decade [7,14–16] (Table 3). Such demographic variations
could be due to differences in the living conditions, ethnicity,
average life span, reporting bias as well as on the diagnostic
criteria utilized. There are speculations of decreasing incidence
of the disease, which is possibly related to improved standards14 vol. 60 j 421–441
Table 1. Causes of Non-cirrhotic portal hypertension (NCPH).
Pre-hepatic
FHVP normal, RAP normal, WHVP normal, HVPG normal, PVP high, ISP high
Extrahepatic portal vein obstruction (EHPVO)
Portal vein thrombosis
Splenic vein thrombosis
Massive splenomegaly
Storage diseases-Gaucher’s disease
Hepatic
FHVP normal, RAP normal, WHVP high, HVPG normal or high, PVP high, ISP high*
Pre-sinusoidal Sinusoidal Post-sinusoidal
Developmental abnormalities Venoocclusive disease
Adult polycystic disease Alcoholic hepatitis Hepatic irradiation
Hereditary hemorrhagic disease Drugs (methotrexate, amiodarone) Toxins-Pyrrolizidine alkaloids
Toxins (vinyl chloride, copper) Drugs-Gemtuzumab, ozogamicin, 
actinomycin D, dacarbazine, cytosine
arabinoside, mithramycin, 6-thioguanine, 
azathioprine, busulfan plus 
cyclophosphamide
Metabolic (NASH, Gaucher’s disease)
Biliary diseases
Primary biliary cirrhosis healed cytomegalovirus, secondary
Sclerosing cholangitis syphilis)
Autoimmune cholangiopathy Sinusoidal collapse Phlebosclerosis of hepatic veins
Toxic-Vinyl chloride Alcoholic liver disease
Neoplastic occlusion of portal vein Sinusoidal defenestration Chronic radiation injury
Lymphoma Alcoholic liver disease (early phase) Hypervitaminosis A
Epithelioid hemangioendothelioma E-ferol injury
Epithelial malignancies Mastocytosis Primary vascular malignancies
Chronic lymphocytic leukemia Agnogenic myeloid metaplasia Epithelioid hemangioendothelioma
Granulomatous lesions Gaucher’s disease Angiosarcoma
Schistosomiasis Amyloidosis Granulomatous phlebitis
Mineral oil granuloma Sinusoidal compression Sarcoidosis
Sarcoidosis By enlarged Kupffer cells (Gaucher’s 
disease, visceral Leishmaniasis)  
By enlarged fat-laden hepatocytes  
(Alcoholic hepatitis, AFLP)
Mycobacterium species
Hepatoportal sclerosis Lipogranulomas
Peliosis hepatitis Mineral oil granuloma
Partial nodular transformation
(HVOTO, Budd-Chiari syndrome)-Idiopathic, 
prothrombotic statesIdiopathic portal hypertension (IPH)
Post-hepatic
FHVP high, RAP normal or high, WHVP high, HVPG normal or high, PVP high, ISP high**
Inferior vena cava obstruction-web, thrombosis, tumour, enlarged caudate lobe
Constrictive pericarditis
Tricuspid regurgitation
Severe right-sided heart failure
Restrictive cardiomyopathy
Splanchnic arteriovenous fistula
Infiltrative diseases-Lymphoma, myeloproliferative disorders
Arteriovenous fistulas
Congenital hepatic fibrosis
Noncirrhotic portal fibrosis (NCPF)/
Inflammatory (viral hepatitis, Q fever,
Acute necro-inflammatory diseases
Sinusoidal infiltration
Sinusoidal fibrosis
Hepatic vein outflow tract obstruction
⁄HVPG not feasible in HVOTO with occlusion of all 3 hepatic veins, or supra- and intrahepatic inferior vena cava obstruction.
⁄⁄Inferior vena cava pressure should also be taken both above and below the opening of hepatic veins.
AFLP, acute fatty liver of pregnancy; FHVP, free hepatic venous pressure; HVPG, hepatic venous pressure gradient (difference between FHVP and WHVP); ISP, intrasplenic
pressure; NASH, non-alcoholic steatohepatitis; PVP, portal vein pressure; RAP, right atrial pressure; WHVP, wedged hepatic venous pressure.
Reviewof hygiene and perinatal care leading to reduction in incidences
of umbilical sepsis and diarrheal episodes in early childhood
[17].
Etiopathogenesis
The precise etiopathogenesis of NCPF/IPH is an area of ongoing
research. Infections and prothrombotic states are commonly422 Journal of Hepatology 201incriminated in the eastern and western patients, respectively
[2].Etiological factors
Rarity of the disease in the west, a declining trend with improved
standards of living and hygienic conditions support the role of
infections, of imprecise nature, at an early age in the disease path-4 vol. 60 j 421–441
Table 2. Diagnostic criteria for non-cirrhotic portal ﬁbrosis/idiopathic portal hypertension.
Japanese criteria for IPH [7]
• Clinical disorder of unknown 
etiology with
• Splenomegaly, anemia and 
portal hypertension with
• Absence of cirrhosis, blood 
disease, parasites in the 
hepatobiliary system, and 
occlusion of the hepatic and 
portal veins
APASL criteria for NCPF/IPH [17]
• Presence of moderate to 
massive splenomegaly
• Evidence of portal 
hypertension, varices, and/or 
collaterals
• Patent spleno-portal axis and 
hepatic veins on ultrasound 
Doppler
• Test results indicating normal 
or near-normal liver functions
• Normal or near-normal HVPG
• Liver histology-no evidence 
of cirrhosis or parenchymal 
injury
Schouten JNL et al., Hepatology 2012 for INCPH [3]$
• Clinical signs of portal hypertension (any one of the 
following):
◦ Splenomegaly/hypersplenism#
◦ Esophageal varices
◦ Ascites (non-  malignant)
◦ Increased HVPG
◦ Portovenous collaterals
• Exclusion of cirrhosis on liver biopsy
• Exclusion of known causes of chronic liver disease 
causing cirrhosis or non-cirrhotic portal hypertension##
◦ Chronic viral hepatitis B and/or C
◦ Non-alcoholic steatohepatitis
◦ Alcoholic steatohepatitis
◦ Autoimmune hepatitis
◦ Hereditary hemochromatosis
◦ Wilson’s disease
◦ Primary biliary cirrhosis
• Exclusion of common conditions causing non-cirrhotic 
portal hypertension
◦ Congenital hepatic fibrosis 
◦ Sarcoidosis
◦ Schistosomiasis
• Patent portal and hepatic veins (on Doppler ultrasound or 
computed tomography scanning)
Additional points*
1. Normal to near-normal liver 
function tests
2. Varices demonstrable by 
endoscopy or radiography
3. Decrease of one or more of the 
formed blood elements
4. Liver scan not typical of 
cirrhosis
5. Patent hepatic veins with a 
normal to slightly elevated WHVP
6. Grossly non-cirrhotic liver 
surface
7. Hepatic histology not indicative 
of cirrhosis
8. Patent extrahepatic portal vein 
with frequent collateral vessels
9. Elevated portal pressure
*Not all these investigations are 
required for diagnosis
Other features:
1. Absence of signs of chronic liver 
disease
2. No decompensation after 
variceal bleed except occasional 
transient ascites
3. Absence of serum markers of 
hepatitis B or C virus infection
4. No known etiology of liver 
disease
5. Imaging with ultrasound or 
other imaging techniques showing 
dilated and thickened portal 
vein with peripheral pruning and 
periportal hyperechoic areas
$All  criteria must be  to diagnose idiopathic 
non-cirrhotic portal hypertension (INCPH)
#Splenomegaly must be accompanied by additional signs of 
portal hypertension to  this criterion
##Chronic liver disease must be excluded, because severe 
 might be understaged on liver biopsyfibrosis
fulfill
fulfilledfive
JOURNAL OF HEPATOLOGYogenesis [2,18]. Endotoxin mediated injury with or without
induced autoimmunity is the proposed hypothesis [19]. Role of
prothrombotic disorders in the pathogenesis is supported by
autopsy studies showing high prevalence of PV thrombosis
(PVT) and studies from the west indicating association with pro-
thrombotic states [14,15]. However, PVT being not a universal
event, absence of acute manifestations of PVT and presence of
increased blood ﬂow in the splenic vein are pointers, which
negate this hypothesis. Prolonged exposure to severalmedications
and toxins especially arsenic has also been incriminated as a
cause [2,3,20,21]. Immunological basis is propagated due to
female preponderance, association with various immunologicalJournal of Hepatology 201and autoimmune disorders, and presence in serum of various
autoantibodies [22]. Lastly, familial clustering, association with
human leukocyte antigen (HLA)-DR3 and with some genetic syn-
dromes suggest a genetic basis [3,23].Animal studies
Various animal models suggesting an infective and immune basis
are shown in Fig. 1 [18,24,25]. NCPF animals develop splenomeg-
aly, high portal pressures, low mean arterial pressures with nor-
mal liver functions and histology, demonstrating the role of
vascular compartment in causing PHT. Also, in the chronic arsenic4 vol. 60 j 421–441 423
Table 3. Epidemiology, clinical features and survival of NCPF/IPH/related disorders by various workers over last 3 decades.
Study (yr)
[Ref.]
Aoki (1998) 
[7]
Vakili (1992) 
[9]
Sarin, Pandey 
(1998, 2006) 
[10,12]
Dhiman (2002) 
[11]
Madhu (2009) 
[13]
Hillaire, Cazals-
Hatem (2002, 
2011) [14,15]
Schouten (2012) 
[16]
Country Japan Iran India India India France Netherlands and 
Belgium
No. of subjects 671 32 207, 336 151 30 28, 46 62
Proportion of total PHT (%) ~33% 21% 9.7% 15% 13.2% - -
Male:Female 1:3 1.5:1 1.3:1, 1:1 1:1.65 1.7:1 2.5: 1, 2:1* 1.06:1
Mean age at diagnosis (yr) 49.9 3rd-4th  decade 30.7, 31.6 30.5 32 41.8, 38.5* 46
Duration of symptoms - 1 mo-18 yr - 15 d-336 mo - -
Clinical features
Mass LUQ - - 12% 69% - - -
Splenomegaly - - 74% 97% 60% (with 36%, 26%* 28%
Anemia - - 90% - anemia) - -
Variceal bleed - 84% 72% 65% 43% 32%, 32%* 55%
Palpable liver - 33% 84.5% 54% - - -
Decompensation - - - 8.6% - - 19%
Ascites - 25% 25% 9.9% 10% - 34%
Edema - - 10%, 18% 4% - - -
Laboratory features
Hypersplenism - - 27% 45.6% 87% 37%* -
Abnormal LFT - 25% 32%, 2% 18% 73% 28.6%, 14%* -
High bilirubin - 31% - 8.8% - -, 30%* -
Deranged INR - 81% 78% 3.9% 27% -, 14%* -
Hypoalbuminemia - - - 16.8% - -, - -
Hemodynamics - -
HVPG >5 mmHg - - 71% 61.5%, 65% -
HVPG (median) 7 mmHg - 12.5 mmHg 6, 7 mmHg* -
Histopathology
Phlebosclerosis - - - 100% - 39%, 96%* 98%
Dilated portal venules - - - 42% 50% -, 38%* 69%
- - - 30% 63% 32%, 30%* -
- - - - 17% 32%, 57%* 94%
NRH - - - - - 18%, 70%* 47%
Dilatated sinusoids - - - - - -, - 98%
Endoscopic features
Esophageal varices - - 92%, 97% - - 43%, 33%* -
Gastric varices - - 22.3%, 31% - - - -
Gastropathy - - 1.6%, - - - -
Colopathy - - 40% - - - -
PP fibrosis
PS fibrosis
⁄Reference [15] included both patients with obliterative portal venopathy and extra-hepatic portal venous obstruction.
INR, international normalized ratio; LFT, liver functions tests; LUQ, left upper quadrant; NRH, nodular regenerative hyperplasia; PP, portal-portal; PS, portoseptal; d, days;
mo, months; yr, years.
Reviewexposure model, there is increased hydroxyproline and collagen
without signiﬁcant hepatic ﬁbrosis [26].
Pathogenesis
Various theories to explain the pathogenesis of NCPF/IPH have
been proposed and are mentioned in Fig. 2 [2,3,27].
Pathology
Liver pathology is characterized by phlebosclerosis, ﬁbroelasto-
sis, periportal, and perisinusoidal ﬁbrosis, aberrant vessels in por-
tal tract (portal angiomatosis), preserved lobular architecture,
and differential atrophy [6,28,29]. Main PV trunk is dilated with
thick sclerosed walls, along with thrombosis in medium and
small PV branches – the histological hallmark termed ‘‘oblitera-424 Journal of Hepatology 201tive portal venopathy’’ [6,29]. Nakanuma et al. had proposed a
staging system based on gross and imaging features: stages I–
IV, stage I being absence of peripheral parenchymal atrophy;
stage IV showing presence of obstructive thrombosis in intrahe-
patic large branches or trunk of PV [29]. Spleen is disproportion-
ately large (average weight 723 g) at portal pressures comparable
to other conditions of PHT [11].Extra-hepatic portal venous obstruction (EHPVO)
Extra-hepatic portal venous obstruction (EHPVO) is a childhood
disorder characterized by a chronic blockage of PV blood supply
leading to PHT and its sequelae in the setting of a well preserved4 vol. 60 j 421–441
Sham animal
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Fig. 1. Animal models of NCPF/IPH. Rabbit models using various interventions either intraportally or via indwelling cannula into gastrosplenic vein or intramuscularly
have been developed [18,24,25]. Studies using albumin [24] and splenic extract [25] favor an immunological basis for NCPF/IPH, whereas those using E. coli favor an
infective basis [18]. We have developed an Endotoxemia Induced PHT (EIPHT) model of NCPF by administering E. coli antigen intramuscularly followed by repeated
injections of the same via gastrosplenic vein (GSV) [19]. In comparison to sham operated animals, NCPF animals have comparable liver histology on hematoxylin and eosin
staining (B vs. A), but there is overexpression of CD34 (J vs. I), a-SMA (L vs. K), cytokeratin-7 (CK-7), endothelial (eNOS) (D vs. C) and inducible (iNOS) nitric oxide synthase (F
vs. E), as well as heme oxygenase (HO)-1 and 2 (H vs. G) enzymes on immunohistochemistry. mRNA as well as protein expression of eNOS, iNOS and HO enzymes were
increased on RT-PCR and Western blot (Panel M and N represent protein expression of e-NOS and HO, respectively). Vasoconstriction and vasorelaxation responses to
phenylephrine and acetylcholine, respectively, were impaired, suggesting endothelial cell dysfunction [19].
JOURNAL OF HEPATOLOGYliver function [4]. EHPVO is a major cause of PHT (54%) and upper
gastrointestinal bleeding in children (68–84%) from the develop-
ing world [30,31]. In the West, non-cirrhotic non-tumoral PVT is
the second most frequent cause of PHT in adults [5], whereas in
children it constitutes a small proportion (11%) [32].
Deﬁnition
As per the APASL consensus, EHPVO is deﬁned as ‘‘a vascular dis-
order of liver, characterized by obstruction of the extra-hepatic
PV with or without involvement of intra-hepatic PV radicles or
splenic or superior mesenteric veins’’ [33]. Although, Baveno V
consensus deﬁnition is more comprehensive and has incorpo-
rated recent thrombus as well as portal cavernoma into the def-
inition, there are certain points to be emphasized [34]. EHPVO is a
distinct disease entity and should neither be considered an eventJournal of Hepatology 201in the natural history nor an association of primary liver disease.
The term ‘‘PVT’’ includes isolated intrahepatic PVT secondary to
cirrhosis or invasion by hepatocellular carcinoma. Also, PVT does
not imply formation of portal cavernoma and development of
PHT, both of which are inherent to long-standing EHPVO. Simi-
larly, isolated occlusion of the splenic vein or superior mesenteric
vein is not included in the deﬁnition of EHPVO as the etiological
spectrum is different. Since the present review relates to NCPH,
‘recent’ or acute thrombosis or PVT is not discussed.Etiopathogenesis
Etiological factors differ among pediatric and adult populations
and despite extensive history and laboratory work-up, up to
70% of cases may remain idiopathic (Table 4).4 vol. 60 j 421–441 425
Possible etiological factors:
Infections: Bacterial, protozoal, schistosomiasis
Drugs and toxins: Arsenic, vinyl chloride, CuSO4, Mtx, 6-MP, 
azathioprine, didanosine, irradiation, vitamin-A
Prothrombotic states: MPD (± JAK2 mutation), MTHFR deficiency, 
protein-C and S deficiency, ACLA, prothrombin gene mutation
Immunological/immunogenetic: SLE, scleroderma, celiac disease, 
primary hypogammaglobulinemia, HLA DR-3
Precipitating event (Infection, trauma, thrombotic event)
Prothrombotic predisposition (Genetic or acquired)
Pathogenic determinants
Splenic sinus lining endothelial
cell in NCPF/IPH
NCPF/IPH EHPVO
Increased iNOS and eNOS
Portal vein radicle
EndMT theory
Endothelial
cells
TGF-β1
Obliteration of small 
and medium branches
of portal vein
Pre-sinusoidal
PHT
(NCPF/IPH)
  Splenic venous inflow,
hyper-dynamic 
circulation Myofibroblast 
like cells
Extracellular
type-1 collagen
deposition
Obliterative 
venopathy
(NCP/IPH) and 
presinulosal PHT
Dual theory
Unifying hypothesis
Nature of insult   Mild, recurring   Severe, progressive
Age   Childhood, adolescence  Neonatal, early childhood
Size of vessel involved Peripheral portal vein branches Main portal vein
Liver
Spleen
Dilatation of splenic sinuses
Fig. 2. Pathogenetic theories for NCPF/IPH. The Unifying hypothesis proposed by Sarin and Kumar gives a common explanation of the pathogenesis of NCPF/IPH and
EHPVO [2]. A major thrombotic event occuring at a young age involves main PV and results in EHPVO, whereas repeated microthrombotic events later in life involve small
or medium branches of PV leading to NCPF. As per dual theory proposed by Schouten et al., both increased splenic blood ﬂow and intrahepatic obstruction (obliterative
venopathy) have a role. High levels of inducible (iNOS) as well as endothelial nitric oxide synthase (eNOS) in splenic endothelial cells lead to dilatation of splenic sinuses
and increased splenic venous inﬂow [3]. Endothelial-mesenchymal transition (EndMT) theory by Sato and Kitao et al. says that vascular endothelial cells of portal venules
acquire myoﬁbroblastic features as evidenced by reduced expression of vascular endothelial cell marker CD34, and increased expression of mesenchymal cell markers
S100A4, a-SMA, COL1A1, and pSmad2. Transforming growth factor-b1 (TGF-b1) acts as a potent inducer of EndMT. Following transformation, these cells synthesize type I
collagen, which causes obliterative portal venopathy and presinusoidal PHT [27]. 6-MP, 6-Mercaptopurine; ACLA, anticardiolipin antibody; CuSO4, copper sulphate; HLA,
human leukocyte antigen; JAK, janus kinase; MPD, myeloproliferative disorders; MTHFR, methylene tetrahydrofolate reductase; Mtx, methotrexate; SLE, systemic lupus
erythematosus.
ReviewEtiological factors
Like other states of venous thrombosis, the factors leading to
EHPVO can be grouped as those within the vessel lumen, within
the wall and outside the vessel; and also as prothrombotic states
(inherited or acquired) and local factors (trauma, injury, inﬂam-
matory conditions). The most common prothrombotic states seen
in children are methylene tetrahydrofolate reductase (MTHFR)426 Journal of Hepatology 201deﬁciency (C677T) and prothrombin gene mutations
(G20201A), whereas in adults, primary myeloproliferative disor-
ders (MPD) (with or without janus kinase 2, JAK2 mutation
V617F) are the commonest. Overall, a single or more prothrom-
botic states are seen in 28–62% of cases, but none of the studies
has screened for all known prothrombotic states [35–59]
(Table 4). In a recent meta-analysis, the prevalence of MPD and4 vol. 60 j 421–441
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JAK2 mutations in PVT was found to be 31.5% and 27.7%, respec-
tively [60]. On the other hand, in a patient with non-malignant
non-cirrhotic PVT, the odds ratios of usage of oral contraceptives,
or presence of prothrombin gene mutation, factor-V Leiden, or
deﬁciencies of protein-C, protein-S and antithrombin-III are 50,
7, 1.5, 5, 3, and 1, respectively [61]. But, direct extrapolation of
these results for EHPVO is unjust. Other conditions leading to
EHPVO are local abdominal inﬂammatory and neoplastic condi-
tions and direct or indirect PV injury secondary to accidental or
non-accidental trauma or iatrogenic causes subsequent to devel-
opment of PVT. Lastly, rare congenital and developmental anom-
alies like PV stenosis, atresia or agenesis can lead to EHPVO,
which are usually associated with other malformations, particu-
larly cardiac [4].
Pathogenesis
A unifying hypothesis to explain the pathogenesis of EHPVO has
already been mentioned [2] (Fig. 2). Umbilical vein catheteriza-
tion (UVC) and sepsis are independently present in 9% of EHPVO
cases [62]. Although, older studies on neonates with UVC, umbil-
ical sepsis or exchange transfusions have shown conﬂicting
results [63,64], subsequent prospective ultrasound (USG) studies
have shown that initial PVT mostly resolves, and progression to
EHPVO doesn’t occur unless umbilical sepsis is very severe, inad-
equately treated with antibiotics or UVC is associated with
trauma [62,65]. Initial acute PVT event in EHPVO often goes
unrecognized and thrombus gradually becomes organized. Multi-
ple hepatopetal collaterals develop around the PV within a span
of 6–20 days and develop into a cavernoma in 3 weeks [66].
These collaterals tend to overcome the prehepatic obstructionTable 4. Etiological factors in EHPVO and PVT in pediatric and adult studies.
Etiological factor
Pediatric studies
Primary myeloproliferative disorders:
with or without janus kinase 2 (JAK2) mutation 
(V617F)
0%
Factor-V Leiden mutation (rs6025) 0-30%
Prothrombin gene mutation (G20201A) 0-15%
MTHFR gene mutation (C677T) 3-34%
Hyperhomocysteinemia NE
0-45%
0-55%
0-50%
Antiphospholipid syndrome/anticardiolipin 
antibodies
3-47%
Paroxysmal nocturnal hemoglobinuria NE
Pancreatitis
Abdominal sepsis
Liver abscess
-
0-5%
6-22%
0-3%
Portal vein injury
(Trauma, splenectomy, pancreatic 
surgery, colectomy, etc)
Umbilical vein catheterization
Umbilical sepsis
0-3%
0-41%
0-45%
Pregnancy -
Oral contraceptives -
Post liver transplant 8%
Idiopathic 45-72%
Protein-C deficiency
Protein-S deficiency
Antithrombin III deficiency
Local inflammatory conditions
Journal of Hepatology 201and terminate in middle-sized intrahepatic PV branches, thus
compensating for a reduction of total hepatic blood ﬂow, but
remain insufﬁcient to decompress high pressure in the splanch-
nic bed. So, hepatofugal vessels do develop at the sites of porto-
systemic communications and transform into varices,
hemorrhoids, and collaterals, some of which may become sponta-
neous shunts [4].
Animal models
Partial PV ligation is the most widely used animal model to study
the hemodynamic changes in EHPVO [67]. However, the limita-
tions are that it is an acute model and prothrombotic states can’t
be studied in it.
Pathology
There is cavernomatous transformation of the PV – cluster of
varying sized vessels replacing PV, arranged haphazardly within
connective tissue support at the liver hilum – which may extend
for a variable length inside and outside the liver. Architectural
pattern of liver is well preserved. Mild periportal ﬁbrosis may
be seen [4].Diagnosis of NCPF and EHPVO
The diagnosis of NCPF and EHPVO is chieﬂy clinical – presenta-
tion with features of PHT without any evidence of liver dysfunc-
tion. Patency of hepatic and portal veins is needed for the
diagnosis of NCPF/IPH, whereas presence of portal cavernoma
on doppler ultrasound (USG) is required for EHPVO. VariousPrevalence [Ref.] 
Adult studies
3-42% 38, 40, 47-50, 52, 54-58
3-14% 37-41, 47-50, 52-54, 57, 58 
0-21% 37-41, 47-49, 52-54, 57, 58
0-21% 53
11-19% 54, 57, 58
3-41% 35, 36, 47-49, 52-54, 57, 58
2-38% 35, 36, 47-49, 52-54, 57
0-41% 35, 47-49, 52-54, 57, 58
1-13% 36, 38, 40, 49, 54, 57, 58
0-2% 49
4-19%
5-36%
0-4%
41-46, 49, 51, 52, 57-61
5-17%
0-2%
<1%
41-47, 49, 51, 58-61
0-2% 49, 52, 57, 58
3-19% 49, 52, 57, 58
1.5% 61
23-68% 41-47, 49, 51, 52, 57, 58
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Fig. 3. Hemodynamics in NCPF/IPH. Both intrasplenic (ISP) and intravariceal pressures (IVP) are high in NCPF. There are two independent pressure gradients – one
between ISP and intrahepatic pressure (IHP) (8.9 mmHg), and another between IHP and wedge hepatic venous pressure (WHVP) (6.2 mmHg), indicating 2 patho-anatomic
sites of resistance in these cases – presinusoidal and perisinusoidal. As the vascular resistance is pre- and peri-sinusoidal, HVPG remains nearly normal [79].
Reviewdiagnostic criteria have been laid down for NCPF/IPH (Table 2).
For EHPVO, the diagnosis is as per the APASL deﬁnition [33].Clinical presentation
NCPF/IPH is a disease of young to middle age, whereas EHPVO is
primarily a childhood disorder but can present at any age from
6 weeks to adulthood [2,4]. The commonest presentations are
well tolerated episodes of variceal bleed, long standing spleno-
megaly and anemia, and in EHPVO, with accompanied growth
retardation (Table 3). In NCPF/IPH, duration of symptoms at pre-
sentation varies from 15 days to 18 years [9,11]. Frequency of
variceal bleeding episodes increase with age with a median of 1
bleeding episode (range 1–20) prior to presentation [11,12]. His-
tory of pica may be present [9].
In EHPVO, a bimodal age of presentation has been described –
those secondary to UVC or umbilical sepsis usually manifest early
(3 years) whereas those following intra-abdominal infections or
idiopathic ones manifest late (8 years) or sometimes into early
adulthood [4,43]. Mean ages of ﬁrst bleeding episode and initial
presentation are 5.3 years and 6.3–9.3 years, respectively, with
a mean number of 1.8–3.1 bleeding episodes per child before pre-
sentation [31,40,68–74]. Episodes of variceal bleed are recurrent,
mostly related to febrile illnesses, are more frequent and severe
with increasing age of onset, but recurrences tend to decrease
after puberty. Splenic size and portal pressure do not correlate
with the incidence or severity of bleed [4].
Hypersplenism, mostly asymptomatic, is present in both the
disorders especially in older children or young adults. Bleeding
from non-gastrointestinal sites is reported in about 20% [13].
Ascites develops in 10–34% of NCPF and 13–21% of EHPVO cases
usually after a bleeding episode and is related to hypoalbumine-428 Journal of Hepatology 201mia, and prolonged duration of PHT with subsequent progressive
deterioration of liver functions [4–13,75]. Other common presen-
tations are repeated attacks of left upper quadrant pain due to
perisplenitis or splenic infarction [2]. Mesenteric vein thrombo-
sis, bowel ischemia, hemoperitoneum, hemobilia, and pulmonary
emboli are rarely seen [57].
On clinical examination, both the disorders have moderate to
massive splenomegaly (average size 11 cm below costal margin).
In NCPF/IPH, liver may be normal, enlarged or slightly shrunken,
whereas in EHPVO, it is normal or shrunken. Peripheral stigmata
of chronic liver disease are absent. Jaundice and hepatic enceph-
alopathy are rare (2%) in NCPF/IPH and usually seen either after
a major bleed or shunt surgery [11]. In EHPVO, jaundice develops
secondary to development of portal biliopathy.
Laboratory ﬁndings
Hypersplenism is seen in 27–87% with anemia being the com-
monest abnormality followed by thrombocytopenia and leuco-
penia. Anemia is usually microcytic hypochromic and is related
to multiple variceal bleeds, hypersplenism and iron deﬁciency
[10–13]. In NCPF/IPH, liver function tests are mostly normal,
but derangements in liver enzymes, prothrombin time and albu-
min are seen in a small proportion [9–15] (Table 3). Similarly, in
EHPVO, elevations of alkaline phosphatase and gamma-glutamyl
transpeptidase are seen with development of portal biliopathy,
and hypoalbuminemia may be seen during bleed episodes [4].
Hypoxemia secondary to intrapulmonary vascular dilatations
may be seen [4]. Frequencies of hepatitis B and C infections are
comparable to that in the general population, but are higher in
transfused patients from remote areas [4,12]. In EHPVO, splenic
stiffness is high and a value above 42.8 kPa predicts variceal
bleed with fairly good accuracy [76].4 vol. 60 j 421–441
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Fig. 4. Algorithmic approach for the diagnosis of EHPVO and management of esophageal and gastric varices. APC, Argon plasma coagulation; EST, endoscopic
sclerotherapy; EVL, endoscopic variceal ligation; GOV, gastroesophageal varices; IGV, isolated gastric varices; PHG, portal hypertensive gastropathy; PNH, paroxysmal
nocturnal hemoglobinuria; RCS, red colour signs; Vx, varix.
JOURNAL OF HEPATOLOGYCoagulation and platelet abnormalities
Prolonged prothrombin time, reduced ﬁbrinogen and reduced
platelet aggregation is seen in around 80% of NCPF/IPH and
EHPVO cases, despite their association with prothrombotic disor-
ders. In addition, patients with EHPVO have a state of low grade
disseminated intravascular coagulation secondary to portosys-
temic shunting [77]. The activity of ADAMTS13 (disintegrin and
metalloproteinase with a thrombospondin type 1 motif, member
13), a zinc-containing metalloprotease, which cleaves the von
Willebrand factor, is signiﬁcantly reduced in patients with
NCPF/IPH [78].Hemodynamics
Intra-splenic (ISP) and intra-variceal pressures (IVP) are signiﬁ-
cantly elevated in both NCPF/IPH as well as EHPVO as compared
to wedge hepatic venous pressures (WHVP) and intrahepatic
pressures (IHP), suggesting a presinusoidal level of block. In
NCPF, two patho-anatomic sites of resistance have been demon-
strated (Fig. 3). HVPG is normal in EHVPO, whereas it is normal or
slightly elevated in NCPF (median 7 mmHg). IVP is the investiga-
tive tool of choice for PHT in both entities. Among bleeders, IVP is
comparable in those with cirrhosis and EHPVO, but at a given
value, cirrhotics are more likely to bleed than EHPVO. In addition,
in EHPVO, hepatic blood ﬂow is normal or decreased, depending
on collateral ﬂow and hepatic arterial buffer response [2,79].Journal of Hepatology 201Hyperdynamic circulatory state has been demonstrated in both
of these disorders [80].
Autonomic dysfunction
Autonomic dysfunction, again secondary to hyperdynamic state
and elevated nitric oxide levels, is present in 25% and 67% of
NCPF/IPH and EHPVO cases, respectively [81,82]. Reduced
alpha-adrenergic vasoresponsiveness in a rabbit model of NCPF/
IPH has been demonstrated, a ﬁnding comparable to cirrhotic
PHT [83].
Immunological alterations
In NCPF/IPH, total peripheral T lymphocytes and suppressor/
cytotoxic phenotype [T8] cells are reduced and the ratio of T4–
T8 cells is signiﬁcantly increased [84]. Vascular cell adhesion
molecule-1 and soluble tumor necrosis factor (TNF)-receptor I
and II are increased in the blood without any signiﬁcant increase
of TNF. Despite heightened Th1 response, cellular inﬁltration is
not so remarkable [85]. Endothelin-1 levels are increased in sple-
nic B lymphocytes, periportal hepatocytes, portal venules, and
hepatic sinusoids [86]. Levels of connective tissue growth factor,
which stimulates in vitro ﬁbroblast proliferation and synthesis of
extracellular matrix, are increased [87]. Mixed autologous lym-
phocytic reaction is defective [88]. It remains to be established,
whether these immunological anomalies are a result or the cause
of NCPF/IPH. Similarly, in EHPVO, predominantly there are abnor-
malities of cell-mediated immunity, whereas humoral immunity4 vol. 60 j 421–441 429
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Fig. 5. Surgical considerations in EHPVO. Pre-operative assessments include those by adult and/or pediatric hepatologist (for growth and to decide timing of surgery and
need for liver biopsy to exclude intrinsic liver disease), cardiologist (echocardiography with or without cardiac catheterization, to exclude HPS and portopulmonary
hypertension), hematologist (for prothrombotic states) and radiologist (CT and MR angiography with or without portography to indicate patency and length of LPV, SMV,
SV, and LRV; patency of hepatic veins, extent of thrombus, size of cavernoma and presence of biliopathy). For absolute indications and patent LPV, Rex-shunt or MLPVB is
the procedure of choice. When the indications of surgery are relative and intrahepatic, LPV could not be assessed preoperatively, then one should not proceed to DSRS
directly and surgery should be delayed until there are absolute indications. LPV, left branch of PV; LRV, left renal vein; SMV, superior mesenteric vein; SV, splenic vein.
Reviewis well preserved. This is explainable by splenic sequestration of T
cells and presence in serum of factors inﬂuencing the kinetics of
lymphocyte response [4].Endoscopic ﬁndings
Esophageal varices are seen in 80–90% of NCPF/IPH and EHPVO
cases [12,89] (Table 4). In comparison to cirrhotics, esophageal
varices are more often large (90% vs. 70%), gastroesophageal
varices (GOV1 and GOV2) more common (31–44% vs. 22%),
portal hypertensive gastropathy (PHG) less common (10.9% vs.
5.4%), and anorectal varices larger and more common (89%
vs. 56%) [89,90]. Isolated gastric varices (IGV1) are present in
around 6% of EHPVO patients and IGV2, indicative of ectopic
or duodenal varices, are also common in these patients [89].
PHG develops usually after variceal eradication and is often
transient, non-progressive and asymptomatic [90]. On initial
endoscopy, if esophageal varices are small, one should look
for gastric varix or spontaneous shunt [17]. In EHPVO, anorec-
tal varices and colopathy are seen in 63–95% and 54% of cases,
respectively – possibly related to selective redistribution of
portal pressure to inferior mesenteric vein. Bleeding from them,
although rare (0.5–10%), may be torrential and life-threatening
[91,92].430 Journal of Hepatology 201Radiological features
Doppler USG is the ﬁrst line radiological investigation in both dis-
orders. In NCPF/IPH, liver is normal in size and echotexture.
Spleen is enlarged with presence of gamma-gandy bodies;
splenoportal axis is dilated and patent in NCPF/IPH. PV is thick-
ened (>3 mm) with echogenic walls and its intrahepatic radicles
are smooth and regular. There is sudden narrowing or cut-off of
intrahepatic second and third degree PV branches – ‘‘withered
tree’’ appearance along with approximation of vascular channels.
Splenic index and PV inﬂow are high [10,11]. Spontaneous shunts
(paraumbilical and gastroadrenorenal) are seen in 16% [11].
Intrahepatic PV abnormalities (non-visualization, reduced cali-
ber, occlusive thrombosis), focal nodular hyperplasia like nodules
and perfusion defects are certain features on contrast-enhanced
computed tomography (CT), which help in differentiating NCPF/
IPH from cirrhosis [93]. Radionuclide scintigraphy using 99mTc-
Sn colloid shows absence of increased bone marrow uptake [8].
For the diagnosis of EHPVO, Doppler USG of SPA has a sensi-
tivity and speciﬁcity above 95% [4]. There is cavernomatous
transformation of PV. Splenoportography or arterial portography
have been replaced by non-invasive methods – CT and magnetic
resonance (MR) angiography and portography, which besides
providing diagnosis also give anatomical road-map prior to shunt
surgery [94].4 vol. 60 j 421–441
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JOURNAL OF HEPATOLOGYLiver biopsy
Liver biopsy is not essential for the diagnosis of EHPVO unless the
underlying chronic liver disease is suspected, but it is indicated in
NCPF/IPH to exclude cirrhosis and other etiologies of PHT [17,33].Journal of Hepatology 201Hillaire et al. have considered 4 pathological ﬁndings for diagno-
sis of NCPF/IPH – hepatoportal sclerosis, periportal ﬁbrosis, peris-
inusoidal ﬁbrosis and nodular regenerative hyperplasia [14].
Diagnosis on liver biopsy is based on a specimen longer than
1 cm with >5 complete portal tracts (CPT) along with alternation4 vol. 60 j 421–441 431
Table 5. Endoscopic outcomes in patients with EHPVO.
Study
(yr)
[Ref.]
No. of 
subjects
(endothe-
rapy)
FU interval Erad of 
eso vx 
No. of 
sessions
Effect Recurrence Change in GVx Change in 
PHG
Mortality Complications
Bleed Eso vx
Yachha
(1997)
[123]
50
(EST)
19 ± 4 mo 88% Mean 8 Reduction in risk of bleed 
0.2/mo to nil 
26% 10% 40% to 70% n.a. 0% n.a.
Zargar
(2004)
[69]
69
(EST)
Median 3 yr 91% 6.3 ± 1.8 Reduction in bleed
0.860 → 0.028 patient-yr
12% 14% n.a. n.a. 1.4% Esophageal ulcers 13%
Strictures 4%
Aspiration 3%
Itha
(2006)
[71]
183
(EST)
3.1 ± 1.8 yr 89% 7.7 ± 1.8 Reduction in GOV1, 
Increase in GOV2, IGV and PHG
7% 
(all 
from 
GVx)
40% GOV1 50 to 34%; 
GOV2 9 to 14%; 
IGV 1 to 9% 
12 to 41%
(severe 
0.6 to 7%)
0% n.a.
Poddar
(2008)
[31]
278
(EST)
34 ± 28 mo 95% 5 ± 2.4 - 3% 14% n.a. n.a. 1.7% Esophageal ulcers 16%
Strictures 17% 
Perforation 2%
Thomas 
(2009)
[72] 
198
(EST)
Median 20 yr n.a. n.a. Recurrence of bleed in mean 5.4 yr, 
Decrease in GOV,
Increase in PHG and GVx
17% 20% GOV1 19 to 2.5%, 
GOV2 13 to 11%, 
IGV1 same
23 to 29% 
(severe
9 to 11%) 
1.5% 
(unrelated 
to EST)
Esophageal stricture 14.6%
Studies on EVL vs. EST
Sarin SK
(1997)
[124]
48
(EST)
47
(EVL)
n.a. n.a. 5.2 ± 1.8
vs.
4.1 ± 1.2
Faster cure, lesser sessions, less 
stricture, PHG and rebleed with EVL
21% 
vs.
6%*
8%
vs.
29%*
GOV1 obliteration 
52% vs. 59%
New PHG 
20% vs.
2%*
6% vs.
6%
Stricture 10% vs. 0%*
Zargar
(2002)
[68]
24
(EST)
25
(EVL)
Mean 22 mo 92%
96%
6.1 ± 1.7
3.9 ± 1.1* 
EST has more complications, early 
cure with EVL 
25%
4%*
10%
17%
n.a. n.a. 0%
0%
25% vs. 4%*
Studies on effect of EST and esophageal variceal eradication on PHG and gastric varices
Yachha
(1996)
[122]
40
(EST)
n.a. n.a. n.a. Increase in PHG n.a. n.a. n.a. 40 to 80% 
(severe 0 
to 50%)
n.a. n.a.
Poddar
(2004)
[70]
274
(EST)
38 ± 30 mo 95% 4.5 ± 1 .9 Reduction in GOV,
Increase in IGV and PHG
3% 4.3% GOV 64 to 45%
IGV 1 to 14%
25% to 
52% 
(severe 3 
to 16%)
2% n.a.
Studies on EVL followed by EST vs. EST 
Poddar
(2011)
[74]
101 
(EVL to 
EST)
60 
(EST) 
33 ± 18 mo
43 ± 17 mo
100%
95%
5.2 ± 1.8
6.8 ± 2.8*
Early cure, less complications with 
EVL followed by EST 
4%
10%
26%
39%
GOV1 52 to 30%; 
GOV2 9 to 22%; 
IGV 3 to 11%
16 to 58% n.a. 7%
28%
Studies on long-term efficacy of EST
Erad, eradication; Eso, esophageal; FU, follow-up; GOV, gastroesophageal varix; GVx, gastric varix; IGV, isolated gastric varix; n.a., not available; RCT, randomized controlled trial.
⁄Indicates signiﬁcant difference with p < 0.05.
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of CPT and central veins to exclude cirrhosis; and more than 2/3
(66%) of CPTs should have absence or reduced caliber portal ven-
ules with sclerosis or thickening of smooth muscle wall [15].
HIV and NCPF/IPH
NCPF/IPH in the setting of HIV and AIDS needs special mention
[21,95,99]. The prevalence of NCPF/IPH in HIV is around 0.45–
1% and is rapidly increasing. This is due to prolonged survival
of HIV infected patients following usage of highly active antiret-
roviral therapy (HAART) and is related to either one or a combi-
nation of the following factors – recurrent opportunistic gut
infections, usage of HAART especially didanosine, hypercoagula-
bility, direct effect of HIV – but the exact mechanism still remains
unclear [21,95,99]. The role of the underlying prothrombotic
state is controversial [21,96,97]. HIV virus itself may be impli-
cated in the disease pathogenesis as indicated by its propensity
to infect hepatic stellate cells and cause endothelial injury via
cytokines like endothelin-1, inerleukins-1 and 6 and platelet
derived growth factor [99]. HIV related NCPF occurs predomi-
nantly in males (50–100%), homosexuals (50–75%), prolonged
infection (median 11.5 years, range 7–15 years) and is associated
with immune reconstitution. Patients with HIV who develop
NCPF are older with reduced platelets and CD4 counts, elevated
liver enzymes, and have longer exposure to didanosine or con-
comitant exposure to stavudine or tenofovir [21,95–98]. Presen-
tation is with features of PHT. Median liver stiffness is 7.8–
10.2 kPa. Median HVPG is 8 mmHg. PVT has been observed in
25–75% [95,96]. Liver decompensation requiring liver transplan-
tation (LTx) has been reported [100].Management of NCPF and EHPVO
The natural course of NCPF/IPH is usually simple, except for
development of PVT and hepatopulmonary syndrome (HPS) in a
few of them, whereas in EHPVO the natural history is more com-
plex because of early insult and is compounded by presence of
growth failure, very slow but progressive parenchymal extinc-
tion, impaired quality of life (QoL), minimal hepatic encephalop-
athy (MHE) and portal biliopathy (Figs. 4–6).
Natural history and prognosis of NCPF
Long term survival after eradication of esophagogastric varices
and after a properly timed shunt surgery is nearly 100% and
80%, respectively [17,101]. Liver functions usually remain well
preserved, but with course of time in 20–33% of cases, liver
slowly undergoes parenchymal atrophy with subsequent decom-
pensation, development of HPS and need for LTx [102,103].
Uncontrolled variceal bleeding is a common cause of death
[17]. In a French follow-up study, PVT, ascites and liver failure
have been shown to develop in 46%, 50%, and 21%, respectively,
over a mean period of 7.6 years – the later 2 complications were
associated with variceal bleeding, surgery or concurrent extrahe-
patic disease [14]. Worsening of preexisting PHT and develop-
ment of new PVT occurred in 46% and 28%, respectively, with a
proportion requiring LTx [15]. Development of PVT is thus con-
sidered a major event contributing to progression of liver disease
and eventual decompensation. However, the same has not been
shown in the transplant and autopsy series [102,103].Journal of Hepatology 201Natural history and prognosis of EHPVO
While the overall prognosis of EHPVO after control of variceal
bleed is good, with long term (>10 years) survival nearly 100%
[4], there are certain issues which need to be addressed.Growth retardation
Stunting and wasting is present in 37–54% and 31–57% of chil-
dren with EHPVO, respectively. Growth depends on duration of
PHT and declines further on follow-up despite appropriate
energy intake [104–107]. Impaired growth is possibly related
to one or more factors – (i) reduced portal blood supply to
liver and deprivation of hepatotropic factors [4]; (ii) poor sub-
strate utilization and/or malabsorption due to portal hyperten-
sive enteropathy, supported by studies demonstrating
improvement in growth indices after portosystemic shunt sur-
gery [107]; (iii) growth hormone (GH) resistance, evidenced by
high levels of GH and low levels of insulin-like growth factor-1
(IGF-1) and IGF binding protein-3 (IGFBP-3) [105–107] and (iv)
anemia and hypersplenism.Impaired quality of life (QoL)
Children with EHPVO have poor health-related QoL with lower
median scores in physical, social, emotional, and school function-
ing health domains as compared to controls. These scores are
unaffected by esophageal eradication and show improving trend
after shunt surgery [107,108].Portal biliopathy
Portal biliopathy refers to biliary ductal (extra- and intra-hepatic)
and gall-bladder wall abnormalities in patients with PHT, which
take the form of intrahepatic biliary radicles dilatation, indenta-
tions, caliber irregularities, displacements, angulations, ectasias,
strictures, common bile duct stones, ﬁlling defects, compressions,
gall-bladder, and pericholedochal varices or a mass (pseudocho-
langiocarcinoma sign). Frequency of these changes in patients
with EHPVO, cirrhosis and NCPF is 80–100%, 0–33%, and 9–40%,
respectively. Increased prevalence of biliopathy in EHPVO is
related to long standing portal cavernoma in the biliary and
peribiliary region, causing compressive and ischemic changes
on the biliary tree, the later ones may remain irreversible even
after shunt surgery [109]. The left hepatic duct is involved more
commonly (38–100%) and severely. Liver histology is essentially
normal. Portal biliopathy usually remains asymptomatic (62–
95%). Common symptoms are jaundice, biliary colic, abdominal
pain and recurrent cholangitis and are seen with old age, long-
standing disease, presence of stones and abnormal liver function
tests [109–113]. ERCP is the diagnostic gold standard, but, being
invasive is indicated in symptomatic cases requiring endothera-
py. A classiﬁcation based on ERCP has been proposed (Fig. 6A)
[109]. MRCP with portography has equal efﬁcacy and is also help-
ful in differentiating choledochal varices from stones. Radiologi-
cally, biliopathy commonly occurs in those EHPVO cases, where
PVT extends into mesenteric veins or bile duct is more acutely
angulated (median 110 vs. 128) [114]. Natural history of biliop-
athy is ill-deﬁned and varies from asymptomatic state to devel-
opment of various sequelae like choledocholithiasis, cholangitis,
and secondary biliary cirrhosis. About 4–10% of portal biliopathy
cases may succumb to these sequelae despite endoscopic treat-
ments [109,111].4 vol. 60 j 421–441 433
Table 6. Surgical outcomes in patients with EHPVO.
Study 
(yr)
No. of subjects
Type of 
surgery/intervention
Indications FU interval Rebleed Success or 
patency of 
shunt
HE or 
MHE
Conclusions Mortality
Bismuth (1980)
n = 52
[128]
PSRS, MCS, 
DSRS, PCS
n.a. 4 yr 2% 94% 0% - 0%
Alvarez (1983)
n = 76
[129]
PSRS, MCS 64 VB
12 prophylactic
Mean 43 mo 8% 92% 0% Resolution of bleeding and improvement in growth in 100% 0%
Warren (1988)
n = 70
[130]
10 Splenectomy
10 Devascularization
25 DSRS
6 Other shunts
12 EST
VB n.a. 4%
50%
4%
67%
28%
-
-
96%
17%
-
n.a
n.a
0%
17%
n.a.
platelet count (99 to 183 x 103/mm3, decrease in spleen volume 
(905 cc to 337 cc at 4.5 yr) 
20%
30%
27%
Gauthier (1989)
n = 59
[131]
PSRS, MCS, 
PCS, H-Type
n.a. Mean 12 mo 7% 92% 0% H-type shunts successful overall in 95% cases; 50% of failed 
intial shunts managed with H-type shunts
n.a.
Mitra (1993)
n = 81
[132]
LRS without 
splenectomy
* Mean 54 mo 10% 84% 0% Improvement in growth, shunt patency correlated with 
disappearance of vx, reduction in spleen size and splenic pulp 
pressure and improvement of hypersplenism
n.a.
Prasad (1994)
n = 160
[133]
PSRS n.a. 12-156 mo 11% n.a. 0% 15-yr survival 95%; pneumococcal meningitis in 1 (0.6%), 
recurrent malaria in 24%
4%
Orloff (1994)
n = 162
[51]
PSRS, MCS Failed EST (49%) 
or surgery (26%)
5-35 yr 2% 98% 0% 5- and 10-yr survivals 99% and 96%
Improvement in QoL and social functioning
1.9%
Menon (2005)
n = 30
[107]
PSRS, LRS, 
Devascularization
n.a. 1-4 yr n.a. 100% n.a. Improvement in WZS in 50% and HZS in 76%
Improved school performance in 85%
Personality improvement in 73%
0%
Wani (2011)
n = 61
[73]
31 Surgery
(RCT)
31 EST 
VB
VB
n.a
n.a.
3%
23%
97% n.a. Less re-bleeding episodes and lesser transfusions in surgery 
group
3%
3%
Studies on Rex shunt (mesenterico-left portal vein bypass, MLPVB)
Stringer (2007)
n = 11
[134]
Rex n.a. n.a. 0% 100% n.a. BMIZS improved from -0.44 to +0.46 0%
Lautz (2009) 
n = 45
[135]
Rex n.a. 5-24 mo 0% 100% n.a. Improvement in WZS from -0.49 to +0.35, 
HZS from -0.42 to -0.14 and 
BMIZS from -0.22 to +0.48
0%
Superina (2006)
n = 34
[136]
Rex 22 VB, 11 
Splenomegaly, 
1 HE following 
shunt
1-7 yr 0% 91% 0% Increase in plts (54 to 160 x103/mm3), WBC (2600 to 4600/mm3), 
decrease in spleen size (11 cm to 3 cm BCM) and PT (16.6 to 
0%
Mack (2006)
n = 12
[137]
9 Rex
3 DSRS
n.a. 1 yr n.a
n.a.
89%
100%
0%
0% vs. non-patent Rex and DSRS
0%
Chaves (2012)
n = 92
[94]
Rex n.a. n.a. n.a. 75% n.a. Pre- and post-operative CT/MR helps in diagnosing patency and 
size of LRV and SMV, shunt stenosis or occlusion
0%
Following DSRS, significant increase in liver blood flow and
13.7 s), increase in SMV flow, LPV diameter and liver volume
Improvement in fluid neurocognitive ability with patent Rex shunt
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Journal of Hepatology 201Minimal hepatic encephalopathy (MHE)
MHE has been described in the setting of EHPVO with or with-
out shunt surgery [115–118]. Post-shunt surgery, there is direct
entry of toxic substances from portal blood into systemic circu-
lation bypassing the liver; prevalence is more with non-selec-
tive as compared to selective shunts. MHE has also been
reported in 32–35% of EHPVO cases without surgical shunt on
the basis of abnormalities in critical ﬂicker frequency, psycho-
metric tests and P300 auditory event-related potential [115].
MHE in EHPVO is associated with presence of spontaneous
shunts, elevated brain glutamine and glutamine/creatine ratio
on 1H-MR spectroscopy, high blood ammonia and proinﬂamma-
tory cytokines (tumour necrosis factor-alpha and IL-6),
increased mean diffusivity on diffusion tensor imaging in sev-
eral areas of the brain, suggesting a role of hyperammonemia
and inﬂammation in its pathogenesis [116,117]. Post shunt sur-
gery, there is further increase in the incidence of MHE along
with ammonia and glutamine/creatine ratio; associated with
decrease in brain myoinositol [118]. MHE persists in 75% and
new onset MHE develops in 5% over 1 year [119]. Usage of lac-
tulose improves MHE in 53% [120].Liver dysfunction
Progressive deterioration of liver functions and ascites may
develop with increasing age, prolonged duration of disease and
development of portal biliopathy. Such patients generally have
reduced hepatic cell mass and synthetic dysfunction [75].
Management
Management in both NCPF/IPH and EHPVO is primarily focused
on management of an acute episode of variceal bleeding followed
by secondary prophylaxis. Other areas deserving attention are
splenomegaly, hypersplenism, growth, portal biliopathy and
MHE, the last three especially in EHPVO. The management of
EHPVO needs to be individualized depending on the age of pre-
sentation, site and nature of obstruction, and clinical manifesta-
tions. Figs. 4–6 show algorithmic management of EHPVO.
Control and prophylaxis of variceal bleed
Variceal bleeding is a severe complication in both NCPF/IPH and
EHPVO. In view of limited data on usage of vasoactive drugs, pro-
panolol, endotherapy and shunt surgery in these 2 conditions,
Baveno V consensus has recommended that the same principles
can be applied [34].
Medical management
Vasoactive drugs, such as somatostatin, octreotide, or terlipres-
sin, should be started early. A single randomized controlled
trial (RCT) in NCPH from our group has shown equal efﬁcacy
of propanolol and endoscopic variceal ligation (EVL) for preven-
tion of rebleeding – 47% showed reduction in grade of varices
and 18% had minor adverse effects in the propanolol group
[121].
Endoscopic variceal obliteration
Endoscopic sclerotherapy (EST) and EVL are effective in 80–90%
of patients in controlling acute bleeding from esophageal varices
and preventing rebleeding. Endotherapy is more effective with
less rebleeding rates when combined with vasoactive drugs.4 vol. 60 j 421–441 435
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EST and EVL have comparable efﬁcacy for eradication of varices.
However, EVL as compared to EST eradicates varices faster, with
lesser complications and rebleed rates, but with increased rate of
variceal recurrence [68–74,122–124] (Table 5). For GOV2 or IGV1
related bleed, glue injection with N-butyl-cyanoacrylate is help-
ful. Endotherapy should be repeated at 2–3 weekly intervals until
variceal eradication [17,34] (Fig. 4).
Surgical management
Surgery is primarily indicated in patients with variceal bleed who
fail to respond to endoscopic management [33,125]. Other indi-
cations are mentioned in Fig. 5. Various types of surgical proce-
dures are:
(i) Shunt/Bypass procedures: Non-physiological shunts bypass
the portal blood either totally or partially into systemic cir-
culation. Total and partial shunts are also known as non-
selective and selective shunts, respectively, as the later
selectively decompress the gastrosplenic zone. Physiologi-
cal shunts, like mesenterico-left PV bypass (MLPVB) or Rex
shunt, maintain the hepatic portal blood ﬂow, while
bypassing the level of obstruction. It decompresses the
splanchnic bed from the superior mesenteric vein to the
left branch of PV via an autologous graft (usually internal
jugular vein).
There are many long-term surgical series on EHPVO,
although the data on NCPF/IPH is limited (Table 6) [51,126–
137]. In NCPF/IPH, following shunt surgery, esophageal varices,
splenic size and splenic pulp pressure reduce [126], but there
is risk of MHE, glomerulonephritis, pulmonary arteriovenous
ﬁstula and ascites [127]. In EHPVO, technical difﬁculty, shunt
thrombosis, rebleeding and MHE are concerns. Improvement
in surgical techniques has largely tackled these issues. Selective
shunts like distal splenorenal shunt (DSRS) are superior to non-
selective ones like central (CSRS) or proximal splenorenal
shunts (PSRS) in terms of patency and lower rebleeding and
encephalopathy rates [4,33]. Physiological shunts actually cure
the disease or defect, and not only the symptoms and sequelae
of PHT. Post-Rex shunt, there is improvement in coagulation
status, growth indices and liver volume, reduction of spleen
size, correction of hypersplenism, reversal of hepatic encepha-
lopathy and improvement in ﬂuid neurocognitive ability in
the form of attention span, processing speed and short-term
memory. MLPVB also prevents development of portal biliopa-
thy and liver disease in adulthood. For these reasons, MLPVB
has become the initial procedure of choice in EHVPO cases
[134–137] (Table 6). Minimum age of 8 years and shuntable
vein size of 6.5 mm were initially advocated for non-selective
shunts, but for MLPVB, minimum reported age is 1 month,
and a vein size of 2 mm is considered adequate [137].
There is limited data to recommend shunt surgery over
endoscopic therapy or vice versa. In a single RCT from India,
comparable mortality and treatment failure has been shown
in both, but with higher rebleeding and blood transfusion
requirement with EST [73]. However, most experts feel that if
there are shuntable veins and the requisite surgical expertise
is available, it is better to do shunt surgery in patients with
EHPVO. This helps in growth recovery and may reduce the
development of gastric and ectopic varices and worsening of
portal biliopathy [4,33,125].436 Journal of Hepatology 201(ii) Ablative procedures: These include esophagogastric devas-
cularization alone or in combination with splenectomy
and are done in patients with failed shunts, those with-
out any shuntable veins, or in emergency situations
with refractory variceal bleed. In view of high rebleeding
rates and mortality, these procedures have become
obsolete [4].
Failure of endoscopic therapy
In 8–12% of cases endotherapy may fail to control acute variceal
bleed. In emergency scenarios surgical ablative procedures, trans-
jugular intrahepatic portosystemic shunt (TIPSS), or balloon-
occluded retrograde transvenous obliteration (BRTO) can be
done – decisions of which remain individualized [33,34].Anticoagulation
In both NCPF/IPH and EHPVO, there is no consensus on the role or
indication of anticoagulation therapy. However, in a known pro-
thrombotic state, this should be considered to prevent recurrent
thrombosis.
Portal biliopathy
It is one of the serious manifestations of long standing EHPVO.
The management is generally supportive and not curative as
the portal cavernoma and PHT continue to compress and afﬂict
the adjoining biliary system. A comprehensive algorithmic
approach for the management of biliopathy is given in Fig. 6B
[109,110,138–141].Follow-up
It is recommended that NCPF/IPH cases should be followed-up at
6 monthly intervals for clinical and laboratory evaluation, close
surveillance for evidence of decompensation and development
of PVT, HPS and biliopathy. EHPVO children need 3 monthly fol-
low-up for growth monitoring, spleen size, QoL, school perfor-
mance, learning abilities, evidence of biliopathy. Endoscopic
surveillance is needed following variceal eradication after every
3–6 months, and in non-bleeders with large and small varices
after every 6 and 12 months, respectively.Miscellaneous causes of NCPH
Apart from NCPF/IPH and EHPVO, there are numerous other
causes of NCPH with a similar presentation. Three of the common
ones have been discussed underneath.Hepatic schistosomiasis
Liver involvement due to schistosomiasis occurs due to one of the
two trematode ﬂukes – Schistosoma mansoni and japonicum.
While the former is seen predominantly in Africa and South
America, the latter is common in eastern Asia, especially main-
land China. The larval forms of the former reside in colonic and
rectal tributaries, whereas those of the later reside in the superior
mesenteric vein. Liver disease develops secondary to entrapment
of eggs in portal venules (<50 mm in diameter) with granuloma-
tous inﬂammation leading to ﬁbrosis (termed ‘‘Symmers pipe-4 vol. 60 j 421–441
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stem ﬁbrosis’’) in 4–8% of cases and subsequent presinusoidal
PHT [142]. Inﬂammatory response elicited by live eggs is initially
of Th1 type with intense granulomatous inﬂammation, but later
on this is substituted by Th2 response with development of ﬁbro-
sis [143]. Deposition of procollagens I, III and IV, as well as its
markers (ﬁbronectin and glycosaminoglycans) is increased – this
is positively regulated by interleukin (IL)-13 and negatively by
gamma-interferon [143,144]. In schistosomal mice models, it
has been demonstrated that various proteins related to stress,
immunity, anti-oxidative response and structural components
are increased, while those related to various metabolic cycles
are decreased [143]. The Foxp3 gene, necessary for generation
of CD4+ CD25+ T reg cells, is overexpressed and ameliorates gran-
uloma formation in such livers [145]. Severe disease is associated
with the HLA-A5 allele and a gene closely linked to interferon-
gamma receptor [142].
Clinical presentation is similar to NCPF and EHPVO. Diagno-
sis is based on demonstration of eggs in stools or rectal biopsy.
Stool microscopy is performed by Kato-Katz method. Serologi-
cal tests for diagnosis are enzyme-linked immunosorbent assay
with soluble antigen of Schistosoma mansoni eggs using sodium
metaperiodate (ELISA-SEA-SMP), alkaline phosphatase immuno-
assay (APIA) and the circumoval precipitin test (COPT) [146].
Sonographically, there is echogenic thickening along PV radi-
cles, and septae giving a ﬁsh-scale network appearance. CT
scan shows capsular and septal calciﬁcations, irregular hepatic
contour, junctional notches, and hypoattenuating bands or
rings around the portal tracts producing a turtle back appear-
ance [142].
Natural history of PHT is closely related to the number of
eggs deposited in the liver, which roughly parallels the number
of eggs excreted in stool of untreated patients. PHT is initially
presinusoidal and gradually becomes perisinusoidal [142].
Treatment with praziquantel leads to complete regression of
periportal thickening in 28.2% of cases within 3–5 years, fol-
lowed by reduction in size of spleen, and diameter of mesen-
teric and splenic veins [146]. A recent metaanalysis has
shown superiority of a combination of artemesinin and prazi-
quantel over praziquantel alone [147]. Management of PHT is
by endotherapy, beta-blockers or surgery. Esophagogastric
devascularization with splenectomy has been shown to
improve hyperdynamic circulatory state with lesser mortality
and complications rates than DSRS in schistosomiasis patients
[148,149].
Congenital hepatic ﬁbrosis
Congenital hepatic ﬁbrosis (CHF) is a rare developmental disor-
der, mostly autosomal recessive in inheritance, primarily affect-
ing the renal and hepatobiliary systems. The underlying
abnormality is ductal plate malformation (DPM), producing
irregularly shaped proliferating intrahepatic bile ducts and per-
iportal ﬁbrosis ultimately leading to PHT. A majority (64%) are
associated with autosomal recessive polycystic kidney disease
(ARPKD), caused by mutations in the PKHD1 gene encoding
for ﬁbrocystin/polycystin protein, which is essential for mainte-
nance of 3-dimensional tubular architecture of renal and biliary
epithelia, thus leading to fusiform dilatations of the renal col-
lecting duct and DPM [150]. Another 25.6% of CHF are associ-
ated with Caroli disease or syndrome and <1% with Type V
choledochal cyst; remaining 9.5% are isolated CHF [150].Journal of Hepatology 201Several other mutations and genetic syndromes have been
described [151]. Median age at diagnosis ranges from 0 to
20 years, with ARPKD and Caroli phenotypes presenting early
with renal insufﬁciency (74%) [150,152]. Presentation with
PHT and cholangitis, although not mutually exclusive, is seen
in 52–86% and 34% of cases, respectively. Esophageal varices
and hypersplenism are present in 40–78% and 44–75%, respec-
tively [150–153]. Ascites, hepatic encephalopathy and HPS are
rare. There is increased predisposition to cholangiocarcinoma
[150]. There is no correlation between renal function and
PHT or severity of liver disease in ARPKD/CHF subtype
[152,153]. Liver functions are essentially preserved except in
the setting of cholangitis and variceal bleed [153]. Imaging
(USG and MRCP) reveals dilatation of biliary system (70%)
and enlargement of left lobe, splenomegaly with or without
hepatic and renal cysts [151]. There is paucity of data on sur-
vival, but mortality is primarily related to sepsis, cholangiocar-
cinoma, variceal bleeding, and very rarely liver failure [150].
PHT is managed primarily with endotherapy and occasionally
surgical shunt. Among various transplant options – single
organ (liver or kidney) or combined liver/kidney (CLKT) – the
decision is based on the age of onset, severity of PHT and renal
insufﬁciency. But, considering high risk of cholangitis and renal
insufﬁciency post isolated kidney and liver transplantation,
respectively, CLKT is the best available option in symptomatic
cases [150]. Neonatal presentation is the best predictor of need
for CLKT in such setting [152].Nodular regenerative hyperplasia
Nodular regenerative hyperplasia (NRH) constitutes around 27%
and 14% of cases of NCPH in Europe and Japan, respectively
[154]. Overall incidence in general population as per autopsy
studies is 2.6% – the rate is 7 times more in people above
80 years of age [155]. Various chemotherapeutic and immuno-
suppressant drugs, hematological, autoimmune, inﬂammatory
and neoplastic disorders are associated with NRH. Pathogenesis
appears to be related to adaptive hyperplastic reaction of hepa-
tocytes in response to mechanical or functional abnormalities
of portal hepatic blood ﬂow [154–157]. Pathologically, there
is partial or complete transformation of the hepatic paren-
chyma into small regenerative nodules (size 1–3 mm), which
sometimes coalesce to form large nodules. Evidence of regener-
ation with absence of ﬁbrous septae between the nodules char-
acteristically differentiates NRH from cirrhosis. Hypertrophied
hepatocytes are located at the center, whereas atrophic ones
at the periphery [154]. Hemodynamically, PHT in NRH is pres-
inusoidal – HVPG is below 12 mmHg in 75%, whereas PV pres-
sure is high [157]. Clinically, a majority of NRH patients remain
asymptomatic; symptomatic ones present with features of PHT
and preserved liver functions [154]. Imaging features are non-
speciﬁc – on USG, nodules appear hypoechoic or isoechoic with
sonoluscent rim; on contrast enhanced CT, they are isodense or
hypodense in both arterial and portal venous phases; while on
contrast enhanced MR, they are hyperintense on T1- and iso-
to hypointense on T2-weighted images [154]. Treatment is
directed towards primary disease. PHT is managed by endo-
therapy, surgical shunt or TIPSS [154,157]. Survival primarily
depends on underlying disease and is not related to PHT or
varices [156].4 vol. 60 j 421–441 437
ReviewKey Points
• Next to cirrhosis, NCPH is a common cause of PHT
• Two disease entities in NCPH, namely NCPF/IPH and
EHPVO are distinct diseases, presenting with features
of PHT – variceal bleed, splenomegaly and near
normal liver functions. Likely pathogenesis is early
age portal inflammation/infection in a prothrombotic
individual
• Diagnosis needs exclusion of cirrhosis in NCPF/IPH
and presence of portal cavernoma in EHPVO
• Slow hepatic dysfunction due to parenchymal 
extinction and portal biliopathy is a late event in 
EHPVO
• Effective management of PHT and its complications
results in excellent 5 and 10 years survivalConﬂict of interest
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